374 related articles for article (PubMed ID: 15604941)
21. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
22. Low-risk papillary thyroid cancer recurrence in patients treated with total thyroidectomy and adjuvant therapy vs. patients treated with partial thyroidectomy.
Hurtado-López LM; Melchor-Ruan J; Basurto-Kuba E; Montes de Oca-Durán ER; Pulido-Cejudo A; Athié-Gutiérrez C
Cir Cir; 2011; 79(2):118-25. PubMed ID: 21631972
[TBL] [Abstract][Full Text] [Related]
23. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
24. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
25. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
26. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
[TBL] [Abstract][Full Text] [Related]
28. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer.
Salvatori M; Rufini V; Reale F; Samanes Gajate AM; Maussier ML; Revelli L; Troncone L; Ardito G
World J Surg; 2003 Jul; 27(7):770-5. PubMed ID: 14509503
[TBL] [Abstract][Full Text] [Related]
29. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
30. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
31. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
[TBL] [Abstract][Full Text] [Related]
32. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of patients to detect recurrent thyroid carcinoma.
Grigsby PW; Baglan K; Siegel BA
Cancer; 1999 Feb; 85(4):945-51. PubMed ID: 10091774
[TBL] [Abstract][Full Text] [Related]
34. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
Lin JD; Chao TC; Huang MJ; Weng HF; Tzen KY
Am J Clin Oncol; 1998 Feb; 21(1):77-81. PubMed ID: 9499265
[TBL] [Abstract][Full Text] [Related]
35. Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?
Hindié E; Zanotti-Fregonara P; Duron F; Keller I; Bouchard P; Devaux JY
Clin Endocrinol (Oxf); 2007 Mar; 66(3):329-34. PubMed ID: 17302864
[TBL] [Abstract][Full Text] [Related]
36. Video-assisted thyroidectomy for papillary thyroid carcinoma.
Bellantone R; Lombardi CP; Raffaelli M; Alesina PF; De Crea C; Traini E; Salvatori M
Surg Endosc; 2003 Oct; 17(10):1604-8. PubMed ID: 12874681
[TBL] [Abstract][Full Text] [Related]
37. Improved survival of patients with papillary thyroid cancer after surgical microdissection.
Tisell LE; Nilsson B; Mölne J; Hansson G; Fjälling M; Jansson S; Wingren U
World J Surg; 1996 Sep; 20(7):854-9. PubMed ID: 8678962
[TBL] [Abstract][Full Text] [Related]
38. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.
Schmidt D; Linke R; Uder M; Kuwert T
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):699-705. PubMed ID: 19936746
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of total thyroidectomy for differentiated thyroid carcinoma: a 20-year review.
Ley PB; Roberts JW; Symmonds RE; Hendricks JC; Snyder SK; Frazee RC; Smith RW; McKenney JF; Brindley GV
Am Surg; 1993 Feb; 59(2):110-4. PubMed ID: 8476139
[TBL] [Abstract][Full Text] [Related]
40. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
